<DOC>
	<DOCNO>NCT01314833</DOCNO>
	<brief_summary>In recent year , increase number breast cancer patient show fact breast cancer one common cancer woman China . However , mortality rate see dramatic decline mainly due early detection breast cancer use effective multimodel treatment . Recent study suggest breast cancer heterogeneous recognize biological subtypes , lead markedly different clinical outcome . Adjuvant chemotherapy widely use treatment primary breast cancer patient . Different type breast cancer cell sensitive different type drugs.There data support information adjuvant chemotherapy regimens different subtypes breast cancer patients， especially Chinese woman . The investigator hypothesize confirm possibility find adjuvant chemotherapy aim different subtypes breast cancer .</brief_summary>
	<brief_title>Efficacy Study Adjuvant Chemotherapy Chinese Primary Breast Cancer Patients</brief_title>
	<detailed_description>Eligibility Female adult ( &gt; 18 year old ) eligible histologically confirm primary breast cancer . Patients also Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 , absolute neutrophil count ( ANC ) &gt; 1500/mm3 , hemoglobin &gt; 8.0g/dL , platelet count &gt; 100,000/mm3 , creatinine &lt; 2.5 time upper limit normal ( ULN ) ） , transaminases &lt; 2.5 time ULN alkaline phosphatase &lt; 4 time ULN transaminase normal , total bilirubin &lt; 2.5 time ULN . Exclusion criterion active infection , pregnancy , primary malignancy ( except situ carcinoma cervix adequately treat nonmelanomatous carcinoma skin ) , document distant metastasis uncontrolled systemic disease . This study protocol approve institutional ethic review board conduct accord guideline good clinical practice Helsinki Declaration . All patient provide write informed consent . Outcome Measures Primary Endpoint：5 year Disease Free Survival（DFS） Second Endpoints：5 year distant disease free survival （DDFS） 5year event free survival （EFS） 5year overall survival （OS）</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Women age 40 65 year old ; 2 . Histologically proven invasive unilateral breast cancer ( regardless type ) ; 3 . Initial clinical condition compatible complete initial resection ; 4 . No residual macro microscopic tumor surgical excision ; 5 . Beginning chemotherapeutic treatment later day 42 initial surgery ; 6 . Node positive disease ( positive sentinel node positive axillary clearance ) ( N+ ) node negative disease ( N ) follow criterion : SBR II / III pT &gt; 20 mm ; 7 . Patient present one follow criterion ( review randomization referent pathologist ) : Luminal A , Luminal B，Her2 overexpressed Hormone receptor negativity define ER &lt; 10 % , PR &lt; 10 % ( IHC ) , HER2 negativity define IHC 01+ , [ IHC 2+ FISH CISH negative ] . 8 . No clinically radiologically detectable metastasis ( M0 ) ; 9 . No peripheral neuropathy &gt; 1 ; 10. WHO Performance status ( ECOG ) 0 1 ; 11 . Adequate recovery recent surgery ( least one week must elapse time minor surgery ( exclude breast biopsy ) ; least three week major surgery ) ; 12 . Adequate hematological function ( neutrophil count ³ 2x109/l , platelet count ³ 100x 109/l , Hemoglobin &gt; 9 g/dl ) ; 13 . Adequate hepatic function : ASAT ALAT £ 1.5 ULN alkaline phosphatases £ 2.5 ULN , total bilirubin £ 1,5 ULN ; 14 . Adequate renal function : serum creatinine £ 1.5 ULN ; 15 . Patients accept contraception intake overall length treatment childbearing potential ; 16 . Adequate cardiac function , LEVF value &gt; 50 % Muga scan echocardiography ; 17 . Signed write informed consent . 1 . Bilateral breast cancer patient controlateral DCIS ; 2 . Any metastatic impairment , include homolateral subclavicular node involvement , regardless type ; 3 . Any tumor ³ T4a ( UICC1987 ) ( cutaneous invasion , deep adherence , inflammatory breast cancer ) ; 4 . Triple negative （ERPRHer2） 5 . Any clinically radiologically suspect nonexplored damage controlateral breast ; 6 . Any chemotherapy , hormonal therapy radiotherapy surgery ; 7 . Previous cancer ( except cutaneous basocellular epithelioma uterine peripheral epithelioma ) precede 5 year , include invasive controlateral breast cancer ; 8 . Patients already include another therapeutic trial involve experimental drug ; 9 . Patients concurrent severe and/or uncontrolled medical disease infection could compromise participation study ; 10 . LEVF &lt; 50 % ( MUGA scan echocardiography ) ; 11 . Clinically significant cardiovascular disease ( e.g . unstable angina , congestive heart failure , uncontrolled hypertension ( &gt; 150/90 ) , myocardial infarction cerebral vascular accident ) within 6 month prior randomization ; 12 . Known prior severe hypersensitivity reaction agent contain Cremophor EL ; 13 . Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period 8 week treatment completion ; 14 . Women pregnant breastfeeding . Adequate birth control measure take study treatment phase ; 15 . Women positive pregnancy test en enrollment prior study drug administration ; 16 . Patients psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial ; 17 . Individual deprive liberty place authority tutor .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Luminal A</keyword>
	<keyword>Luminal B</keyword>
	<keyword>Her-2 overexpression</keyword>
	<keyword>DFS</keyword>
	<keyword>DDFS</keyword>
	<keyword>OS</keyword>
</DOC>